tirzepatide burning at injection site How Deep to Inject Tirzepatide: Proper Subcutaneous Technique Guide Injection Site Reactions Increasing :

Lancet (London England) (2018) 392(10157):151929

Best For Patients who have plateaued on semaglutide or tirzepatide Patients with significant weight to lose (50+ pounds) Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome Patients who want access to the most advanced mechanism currently available Patients with established GLP-1 experience and good tolerance Side Effect Comparison All three medications share a similar side effect profile driven primarily by gastrointestinal effects: Common Side Effects (All Three) Nausea most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level Diarrhea reported by 15 to 25 percent of patients Vomiting reported by 8 to 15 percent Constipation reported by 6 to 12 percent Decreased appetite nearly universal and considered therapeutic Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation

(3) Peter B

Semaglutide primarily reduces joint pain through weight loss and resulting metabolic improvements rather than direct anti-inflammatory action on joint tissue

B., Wang, H., and Li, Y

Baldo BA (2015) Enzymes approved for human therapy: indications, mechanisms and adverse effects